ClassID:

170534

G01N2333/811 - CPC Classification

Classification description:

Assays involving biological materials from specific organisms or of a specific nature; Protease inhibitors; Endopeptidase (E.C. 3.4.21-99) inhibitors Serine protease (E.C. 3.4.21) inhibitors

Sub-classes:
Recent Application in this class:
#1
20260130975
2026-05-14

INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF

#2
20260028679
2026-01-29

BIOMARKER FOR DIAGNOSIS OF GASTRIC CANCER

#3
20250270292
2025-08-28

THERAPEUTIC VARIANT ALPHA-2-MACROGLOBULIN COMPOSITIONS

#4
20250073704
2025-03-06

FLUID TRANSFER DEVICES WITH INTEGRATED FLOW-BASED ASSAY AND METHODS OF USING THE SAME FOR IDENTIFYING SEPSIS

#5
20240295567
2024-09-05

HYPOXIA BIOMARKER AND USE THEREOF

#6
20240241127
2024-07-18

METHOD FOR DETERMINING PROSTATE CANCER

#7
20230250154
2023-08-10

Therapeutic variant alpha-2-macroglobulin compositions

#8
20230117596
2023-04-20

Clinical diagnosis of non-alcoholic fatty liver disease using a panel of human blood protein biomarkers

#9
20220380833
2022-12-01

Universal Calibration Method for Assaying Enzymatic Inhibitors

#10
20220273810
2022-09-01

ANTI-SERINE PROTEASE INHIBITOR KAZAL (SPIK) ANTIBODIES, IMMUNOCONJUGATES, AND METHODS OF USE

#11
20220106627
2022-04-07

METHODS OF DIAGNOSING TUBERCULOSIS AND DIFFERENTIATING BETWEEN ACTIVE AND LATENT TUBERCULOSIS

#12
20210393750
2021-12-23

INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF

#13
20210147511
2021-05-20

Therapeutic variant alpha-2-macroglobulin compositions

#14
20200348311
2020-11-05

Methods for quantitation of functional C1 esterase inhibitor (FC1-INH)

#15
20200173990
2020-06-04

Detection of citrullinated inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4)

#16
20200148748
2020-05-14

Therapeutic variant alpha-2-macroglobulin compositions

#17
20190359690
2019-11-28

THERAPEUTIC VARIANT ALPHA-2-MACROGLOBULIN COMPOSITIONS

#18
20190339288
2019-11-07

Clinical diagnosis of non-alcoholic fatty liver disease using a panel of human blood protein biomarkers

#19
20190285637
2019-09-19

BIOMARKERS FOR GASTRIC CANCER AND USES THEREOF

#20
20190136292
2019-05-09

Universal Calibration Method for Assaying Enzymatic Inhibitors

#21
20190072555
2019-03-07

MULTIPLEX ASSAYS FOR EVALUATING PROSTATE CANCER STATUS

#22
20180143205
2018-05-24

BIOMARKERS FOR PREDICTING DEGREE OF WEIGHT LOSS IN FEMALE SUBJECTS

#23
20180003724
2018-01-04

ALZHEIMER'S DISEASE DIAGNOSTIC PANELS AND METHODS FOR THEIR USE

#24
20170355749
2017-12-14

Therapeutic variant alpha-2-macroglobulin compositions

#25
20170030928
2017-02-02

Protein biomarkers for immune assessment and prediction of transplant rejection

#26
20160370373
2016-12-22

Biomarkers for gastric cancer and uses thereof

#27
20160319372
2016-11-03

METHOD FOR PREDICTING THE SURVIVAL STATUS AND PROGNOSIS OF ESOPHAGEAL CANCER AND A KIT THEREOF

#28
20160011218
2016-01-14

Analysis of direct factor Xa inhibitors

#29
20150344935
2015-12-03

Analysis of direct factor Xa inhibitors

#30
20150260657
2015-09-17

ASSAYS FOR DETECTION OF GLYCOSAMINOGLYCANS

#31
20150219672
2015-08-06

Biomarkers for non-alcoholic fatty liver disease, and methods for detecting non-alcoholic fatty liver disease by using such biomarkers

#32
20150204888
2015-07-23

Quantifying local inflammatory activity and its use to predict disease progression and tailor treatments

#33
20150198618
2015-07-16

ALZHEIMER'S DISEASE DIAGNOSTIC PANELS AND METHODS FOR THEIR USE

#34
20150185227
2015-07-02

MARKER FOR PRETERM LABOUR

#35
20140348854
2014-11-27

HE4 based therapy for malignant disease

#36
20130281309
2013-10-24

Novel biomarker for non-alcoholic fatty liver disease, and method for detecting non-alcoholic fatty liver disease by using the biomarker

#37
20130029850
2013-01-31

Competitive Differential Screening

#38
20120238476
2012-09-20

ALZHEIMER'S DISEASE DIAGNOSTIC PANELS AND METHODS FOR THEIR USE

#39
20120028369
2012-02-02

Quantifying local inflammatory activity and its use to predict disease progression and tailor treatments

#40
20120028269
2012-02-02

Methods for detection of gastric cancer

#41
20110098184
2011-04-28

Competitve differntial screeing

#42
20100297679
2010-11-25

Identification and quantification of biomarkers for evaluating the risk of preterm birth

#43
20100240083
2010-09-23

METHOD FOR THE DETECTION OF THE IN-VIVO ACTIVITY OF NEUROTRYPSIN, USE OF THE METHOD AND USE OF THE C-TERMINAL, 22-KDA FRAGMENT OF AGRIN AS BIOMARKER IN DIAGNOSIS AND MONITORING OF NEUROTRYPSIN-RELATED DISTURBANCES

#44
20100129828
2010-05-27

Method of assaying leukocyte elastase inhibitor for the in vitro diagnosis of colorectal cancer

#45
20090275068
2009-11-05

Method of determining chymase activity with secretory leukocyte protease inhibitor

#46
20090118191
2009-05-07

Anti-Antiogenic Fragments of Pigment Epithelium-Derived Factor (PEDF)

#47
20080312420
2008-12-18

Monoclonal antibodies for detection of urinary trypsin inhibitors

#48
20080293626
2008-11-27

Pigment epithelium-derived factor as a therapeutic agent for vascular leakage

#49
20080138843
2008-06-12

Method for determining the total clotting activity of a blood or plasma sample

#50
20070166779
2007-07-19

Method of determining chymase activity with secretory leukocyte protease inhibitor

#51
20070160981
2007-07-12

VIRAL PROTEASE

#52
20070020683
2007-01-25

Monoclonal antibodies for detection of urinary trypsin inhibitors

#53
20060189519
2006-08-24

Anti-angiogenic fragments fo pigment epithelium-derived factor (pedf)

#54
20060177432
2006-08-10

Methods and reagents for protease inhibition

#55
20050037009
2005-02-17

Methods and reagents for protease inhibition